First Patient Dosed in First-in-human trial of AGX101, a Novel ADC targeting TM4SF1

A first patient has been dosed in a Phase 1 clinical study (NCT06440005) with AGX101, a novel TM4SF1-directed Nuclear-Delivered Antibody-Drug Conjugate™ (ND-ADC) therapy for the treatment of solid tumors. AGX101, which is being developed by privately held biotech startup Angiex, is based on a new, groundbreaking ADC technology platform with a unique mechanisms of action.

Authors

Publication Details

Journal
ADC Review / Journal of Antibody-drug Conjugates
Published
2024-08-08
DOI
https://doi.org/10.14229/jadc.2024.08.08.001
Primary Topic
Monoclonal and Polyclonal Antibodies Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

First Patient Dosed in First-in-human trial of AGX101, a Novel ADC targeting TM4SF1

Peter Hofland
ADC Review / Journal of Antibody-drug Conjugates
Monoclonal and Polyclonal Antibodies Research
article

First Patient Dosed in First-in-human trial of AGX101, a Novel ADC targeting TM4SF1

Peter Hofland
article en

Abstract

A first patient has been dosed in a Phase 1 clinical study (NCT06440005) with AGX101, a novel TM4SF1-directed Nuclear-Delivered Antibody-Drug Conjugate™ (ND-ADC) therapy for the treatment of solid tumors. AGX101, which is being developed by privately held biotech startup Angiex, is based on a new, groundbreaking ADC technology platform with a unique mechanisms of action.

ADC Review / Journal of Antibody-drug Conjugates
Openalex Percentile: Top 78%
Monoclonal and Polyclonal Antibodies Research
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

First Patient Dosed in First-in-human trial of AGX101, a Novel ADC targeting TM4SF1 — Peter Hofland · ADC Review / Journal of Antibody-drug Conjugates (2024) | TGRS Research Map | TGRS